Journal of Clinical Oncology, Vol 5, 1340-1347, Copyright © 1987 by American Society of Clinical Oncology

ARTICLES

Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation

FR Appelbaum, KM Sullivan, CD Buckner, RA Clift, HJ Deeg, A Fefer, R Hill, J Mortimer, PE Neiman and JE Sanders

Between July 1970 and January 1985, 100 patients with malignant lymphoma were treated with high-dose chemoradiotherapy and bone marrow transplantation. Twenty-eight of the 100 are alive and the actuarial probability of disease-free survival 5 years from transplantation is 22%. The most common reason for treatment failure was disease recurrence, with an actuarial probability of 60%. A proportional hazards regression analysis showed that the likelihood of disease-free survival was less in those patients transplanted in resistant relapse and in those previously treated with chest radiotherapy. Neither disease histology (Hodgkin's disease, high-grade lymphoma or intermediate-grade lymphoma), nor source of marrow (syngeneic, allogeneic, or autologous) significantly influenced either disease-free survival or probability of relapse. The use of high-dose chemoradiotherapy and marrow transplantation appears to offer a better chance for long-term survival than any other form of therapy for young patients with disseminated malignant lymphoma whose disease has progressed after initial combination chemotherapy. The best results with marrow transplantation were obtained in patients transplanted in early relapse or second remission who had not received prior chest radiotherapy.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. Matsumoto, H. Wada, H. Nishiyama, T. Hirano, M. Sakakura, K. Nishii, M. Masuya, S. Kageyama, S. Tamaki, K. Nakase, et al. Hemostatic Abnormalities and Changes Following Bone Marrow Transplantation Clinical and Applied Thrombosis/Hemostasis, October 1, 2004; 10(4): 341 - 350. [Abstract] [PDF]

				P. J. Bierman, J. W. Sweetenham, F. R. Loberiza Jr, G. Taghipour, H. M. Lazarus, J. D. Rizzo, N. Schmitz, K. van Besien, J. M. Vose, M. Horowitz, et al. Syngeneic Hematopoietic Stem-Cell Transplantation for Non-Hodgkin's Lymphoma: A Comparison With Allogeneic and Autologous Transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation J. Clin. Oncol., October 15, 2003; 21(20): 3744 - 3753. [Abstract] [Full Text] [PDF]

				S. Tamaki, H. Wada, K. Ohfuzi, T. Shibata, M. Masuya, S. Kageyama, E. C. Gabazza, K. Kawakami, K. Tsuji, E. Miyanishi, et al. Hemostatic Abnormalities Following Bone Marrow Transplantation Clinical and Applied Thrombosis/Hemostasis, April 1, 2002; 8(2): 125 - 132. [Abstract] [PDF]

				V. T. Ho and R. J. Soiffer The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation Blood, December 1, 2001; 98(12): 3192 - 3204. [Full Text] [PDF]

				H. C. Kluin-Nelemans, V. Zagonel, A. Anastasopoulou, D. Bron, K. J. Roozendaal, E. M. Noordijk, H. Musson, I. Teodorovic, B. Maes, A. Carbone, et al. Standard Chemotherapy With or Without High-Dose Chemotherapy for Aggressive Non-Hodgkin's Lymphoma: Randomized Phase III EORTC Study J Natl Cancer Inst, January 3, 2001; 93(1): 22 - 30. [Abstract] [Full Text] [PDF]

				T. Kewalramani, A. D. Zelenetz, E. E. Hedrick, G. B. Donnelly, S. Hunte, A. C. Priovolos, J. Qin, N. C. Lyons, J. Yahalom, S. D. Nimer, et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis Blood, October 1, 2000; 96(7): 2399 - 2404. [Abstract] [Full Text] [PDF]

				M. S. Kaminski, J. Estes, K. R. Zasadny, I. R. Francis, C. W. Ross, M. Tuck, D. Regan, S. Fisher, J. Gutierrez, S. Kroll, et al. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience Blood, August 15, 2000; 96(4): 1259 - 1266. [Abstract] [Full Text] [PDF]

				C. Aristei and A. Tabilio Total-Body Irradiation in the Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoproliferative Diseases Oncologist, October 1, 1999; 4(5): 386 - 397. [Abstract] [Full Text]

				Z. S. Pavletic and J. O. Armitage Bone Marrow Transplantation for Cancer--An Update Oncologist, June 1, 1996; 1(3): 159 - 168. [Abstract] [Full Text] [PDF]

				J. O. Armitage Bone Marrow Transplantation N. Engl. J. Med., March 24, 1994; 330(12): 827 - 838. [Full Text]

				O. W. Press, J. F. Eary, F. R. Appelbaum, P. J. Martin, C. C. Badger, W. B. Nelp, S. Glenn, G. Butchko, D. Fisher, B. Porter, et al. Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support N. Engl. J. Med., October 21, 1993; 329(17): 1219 - 1224. [Abstract] [Full Text]

				B. D. Cheson, L. Lacerna, B. Leyland-Jones, G. Sarosy, and R. E. Wittes Autologous Bone Marrow Transplantation: Current Status and Future Directions Ann Intern Med, January 1, 1989; 110(1): 51 - 65. [Abstract] [PDF]